NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) An
Post# of 112
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has entered into a securities purchase agreement. The company entered the agreement, which calls for the issue and sale of 742,626 shares of common stock (or prefunded warrants in lieu thereof) with a healthcare-focused institutional investor. The company also noted it had entered into additional agreement and placements with current investors as well as directors and officers of Clene. Gross proceeds from the transactions will total an estimated $7.3 million, before standard deductions and fees. Canaccord Genuity is acting as sole placement agent for the offerings, which are expected to close on or about Oct. 1, 2024.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer